# 116-hr-6260: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020

116-hr-6260, Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020, is a 116th Congress bill sponsored by Rep. Roy, Chip [R-TX-21] (R-TX); status Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (as of 2025-11-18).

- Canonical: https://policyrisk.com/legislation/116-hr-6260
- As of: 2025-11-18
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 116-hr-6260
- Congress: 116
- Title: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020
- Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced: 2020-03-12
- Sponsor: Rep. Roy, Chip [R-TX-21] (R-TX)
- Cosponsors: 1
- Policy area: Health
- Touches household money: no
- Last recorded action: 2025-11-18

## Summary

Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020 This bill establishes a reciprocal marketing approval process that allows for the sale of a drug, biological product, or medical device that has not been approved by the Food and Drug Administration (FDA) if the product is approved for sale in another country for the treatment or prevention of COVID-19 (i.e., coronavirus disease 2019) and there is an unmet need relative to certain diseases. Specifically, the bill requires the product's sponsor to demonstrate, among other things, that the product has been approved for the treatment or prevention of COVID-19 or another disease of epidemic potential, the approval is in one of the specified countries, the FDA and listed countries have not withdrawn approval because of safety or effectiveness concerns, and there is a public health or unmet medical need for the product. The FDA may only decline approval if the FDA determines that the product is not safe or effective. The FDA must make such a determination not later than 30 days after receiving a request. Congress may pass a joint resolution to grant reciprocal marketing approval of a product that the FDA declines to approve through the reciprocal process.

## Cosponsors (1)

- Rep. Schweikert, David [R-AZ-1] (R-AZ), 2020-04-17T00:00:00.000Z

## Related bills

- 116-hr-7010: Paycheck Protection Program Flexibility Act of 2020
- 116-hr-6886: Paycheck Protection Program Flexibility Act of 2020
- 116-hr-6821: Small Business Expense Protection Act of 2020
- 116-hr-6742: Protecting Life in Crisis Act
- 116-hr-4692: Countering Turkish Aggression Act of 2019
- 116-hr-4305: PAWS for Veterans Therapy Act

## Sources
- [116-hr-6260 on Congress.gov](https://www.congress.gov/bill/116th-congress/house-bill/6260)

## Related
- [116-hr-7010: Paycheck Protection Program Flexibility Act of 2020](https://policyrisk.com/legislation/116-hr-7010)
- [116-hr-6886: Paycheck Protection Program Flexibility Act of 2020](https://policyrisk.com/legislation/116-hr-6886)
- [116-hr-6821: Small Business Expense Protection Act of 2020](https://policyrisk.com/legislation/116-hr-6821)
- [116-hr-6742: Protecting Life in Crisis Act](https://policyrisk.com/legislation/116-hr-6742)
- [116-hr-4692: Countering Turkish Aggression Act of 2019](https://policyrisk.com/legislation/116-hr-4692)
- [116-hr-4305: PAWS for Veterans Therapy Act](https://policyrisk.com/legislation/116-hr-4305)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/116-hr-6260 (as of 2025-11-18).